PHARMACYTE BIOTECH, INC. Other Comprehensive Income (Loss), Net of Tax
PHARMACYTE BIOTECH, INC. (PMCB) reported Other Comprehensive Income (Loss), Net of Tax of -$615 for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-09-14
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-07-31 was -$615.00, a 600.00% decline year-over-year.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-04-30 was $744.00, a 20.58% increase year-over-year.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-01-31 was $2.59K.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-10-31 was -$381.00, a 724.59% decline year-over-year.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), net of tax for fiscal 2026 was $3.07K.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), net of tax for fiscal 2025 was -$358.00.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), net of tax for fiscal 2024 was -$508.00.
- PHARMACYTE BIOTECH, INC. other comprehensive income (loss), net of tax for fiscal 2023 was -$7.25K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$615.00 10-Q · filed 2026-09-14 | $129.00 derived: sum of 2 quarters · filed 2026-09-14 | $2.72K derived: sum of 3 quarters · filed 2026-09-14 | $2.33K derived: sum of 4 quarters · filed 2026-09-14 |
| 2026-04-30 | $744.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | $3.33K derived: sum of 2 quarters · filed 2026-07-29 | $2.95K derived: sum of 3 quarters · filed 2026-07-29 | $3.07K 10-K · filed 2026-07-29 |
| 2026-01-31 | $2.59K 10-Q · filed 2026-03-17 | $2.21K derived: sum of 2 quarters · filed 2026-03-17 | $2.33K 10-Q · filed 2026-03-17 | $2.95K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-10-31 | -$381.00 10-Q · filed 2025-12-18 | -$258.00 10-Q · filed 2025-12-18 | $359.00 derived: sum of 3 quarters · filed 2026-09-14 | -$860.00 derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-07-31 | $123.00 10-Q · filed 2026-09-14 | $740.00 derived: sum of 2 quarters · filed 2026-09-14 | -$479.00 derived: sum of 3 quarters · filed 2026-09-14 | -$418.00 derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-04-30 | $617.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | -$602.00 derived: sum of 2 quarters · filed 2026-07-29 | -$541.00 derived: sum of 3 quarters · filed 2026-07-29 | -$358.00 10-K · filed 2026-07-29 |
| 2025-01-31 | -$1.22K 10-Q · filed 2026-03-17 | -$1.16K derived: sum of 2 quarters · filed 2026-03-17 | -$975.00 10-Q · filed 2026-03-17 | -$1.41K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-10-31 | $61.00 10-Q · filed 2025-12-18 | $244.00 10-Q · filed 2025-12-18 | -$194.00 derived: sum of 3 quarters · filed 2025-12-18 | $876.00 derived: sum of 4 quarters · filed 2025-12-18 |
| 2024-07-31 | $183.00 10-Q · filed 2025-09-15 | -$255.00 derived: sum of 2 quarters · filed 2025-09-15 | $815.00 derived: sum of 3 quarters · filed 2025-09-15 | -$776.00 derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | -$438.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-11 | $632.00 derived: sum of 2 quarters · filed 2025-08-11 | -$959.00 derived: sum of 3 quarters · filed 2025-08-11 | -$508.00 10-K · filed 2025-08-11 |
| 2024-01-31 | $1.07K 10-Q · filed 2025-03-17 | -$521.00 derived: sum of 2 quarters · filed 2025-03-17 | -$70.00 10-Q · filed 2025-03-17 | -$5.35K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-10-31 | -$1.59K 10-Q · filed 2024-12-13 | -$1.14K 10-Q · filed 2024-12-13 | -$6.42K derived: sum of 3 quarters · filed 2024-12-13 | -$8.97K derived: sum of 4 quarters · filed 2024-12-13 |
| 2023-07-31 | $451.00 10-Q · filed 2024-09-17 | -$4.83K derived: sum of 2 quarters · filed 2024-09-17 | -$7.38K derived: sum of 3 quarters · filed 2024-09-17 | -$8.10K derived: sum of 4 quarters · filed 2024-09-17 |
| 2023-04-30 | -$5.28K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-13 | -$7.83K derived: sum of 2 quarters · filed 2024-08-13 | -$8.55K derived: sum of 3 quarters · filed 2024-08-13 | -$7.25K 10-K · filed 2024-08-13 |
| 2023-01-31 | -$2.55K 10-Q · filed 2024-03-18 | -$3.27K derived: sum of 2 quarters · filed 2024-03-18 | -$1.97K 10-Q · filed 2024-03-18 | |
| 2022-10-31 | -$720.00 10-Q · filed 2023-12-15 | $584.00 10-Q · filed 2023-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |